Human embryo editing against disease is unsafe and unproven — despite rosy predictions
Shai Carmi,
No information about this author
Henry T. Greely,
No information about this author
Kevin J. Mitchell
No information about this author
et al.
Nature,
Journal Year:
2025,
Volume and Issue:
637(8046), P. 554 - 556
Published: Jan. 8, 2025
Language: Английский
Should biology put complexity first?
Cell Systems,
Journal Year:
2025,
Volume and Issue:
unknown, P. 101197 - 101197
Published: Feb. 1, 2025
Language: Английский
The Last Mile in Beta-Cell Replacement Therapy for Type 1 Diabetes: Time to Grow Up
Transplant International,
Journal Year:
2025,
Volume and Issue:
38
Published: April 1, 2025
Beta
cell
replacement
therapy
for
type
1
diabetes
(T1D)
is
undergoing
a
transformative
shift,
driven
by
advances
in
stem
biology,
gene
editing,
and
tissue
engineering.
While
islet
transplantation
has
demonstrated
proof-of-concept
success
restoring
endogenous
insulin
production,
its
clinical
impact
remains
limited
donor
scarcity,
immune
rejection,
procedural
complexities.
The
emergence
of
cell-derived
beta-like
cells
represents
paradigm
with
initial
trials
showing
promising
secretion
vivo.
However,
translating
these
breakthroughs
into
scalable,
widely
accessible
treatments
poses
significant
challenges.
Drawing
parallels
to
space
exploration,
this
paper
argues
that
while
scientific
feasibility
been
demonstrated,
true
accessibility
elusive.
Without
strategic
beta
risks
becoming
an
elite
intervention,
restricted
cost
infrastructure.
Lessons
from
therapies
rare
diseases
highlight
the
dangers
unsustainable
pricing
market
viability.
To
bridge
"last
mile"
Quality
Design
approach
proposed,
emphasizing
scalability,
ease
use,
economic
outset.
By
practical
implementation
over
academic
achievements,
corporate
interests,
economics,
or
patent
constraints,
can
progress
viable,
treatment.
Language: Английский
Polarizing biotechnologies and a polarized public
Journal of Ethics and Emerging Technologies,
Journal Year:
2025,
Volume and Issue:
35(2), P. 1 - 9
Published: March 10, 2025
The
rapid
advancements
in
genome
editing,
particularly
with
CRISPR-Cas9,
have
brought
long-promised
medical
breakthroughs
to
reality,
but
also
has
accelerated
ethically
fraught
applications.
To
develop
adequate
ethical
safeguards
and
effective
governance,
many
endorse
public
engagement
as
an
essential
aspect
of
this
response.
This
paper
tests
confidence
by
applying
it
emerging
existential
risk
that
development
when
combined
similarly
rapidly
growing
socio-political
polarisation,
poses
liberal
democracy.
While
argument
some
echoes
Maxwell
Mehlman’s
spectre
a
genetically
enhanced
"genobility"
destroying
the
basis
democracy,
I
outline
how
new
concern
is
more
plausible,
immediate
and,
moreover,
possibly
far
intractable
problem
than
Mehlman
was
considering.
exacerbated
considering
perception
editing’s
potential—rather
its
actual
capabilities—may
be
affected
turn,
may
worsen
rising
polarisation.
Given
positive
role
respect
technology
involved
here,
evaluate
effectiveness,
arguing
certain
forms
inadvertently
things,
whereas
stronger
deliberative
approaches
hold
promise
face
significant,
potentially
insurmountable,
barriers,
at
least
for
now.
Language: Английский